Supplementary File 1 from Safety and Tolerability of a Novel Anti-HER2 Antibody-Drug Conjugate (PF-06804103) in Patients With HER2-Expressing Solid Tumors: A Phase 1 Dose Escalation Study | Synapse
September 16, 2024
Supplementary File 1 from Safety and Tolerability of a Novel Anti-HER2 Antibody-Drug Conjugate (PF-06804103) in Patients With HER2-Expressing Solid Tumors: A Phase 1 Dose Escalation Study
Key Points
Key points are not available for this paper at this time.
Abstract
Supplementary File 1 shows the Methods and Results for Part 1B
AI에게 질문
Like
Bookmark
Share
AI에게 질문
Like
Bookmark
Share
Cite This Study
Meric‐Bernstam et al. (Mon,) studied this question.